TRX319

About Tr1X

Tr1X is pioneering a new category of cell therapy focused on immune regulation rather than immune destruction. The company leverages deep immunology expertise and genetic engineering to create stable, scalable Tr1 cell therapies designed to home to sites of inflammation and induce long-term tolerance. With its lead program, TRX103, already demonstrating initial clinical proof of safety and mechanism in GvHD, Tr1X is advancing a multi-program pipeline targeting major autoimmune conditions like Crohn's disease and multiple sclerosis.

Therapeutic Areas

Other Crohn's Disease Drugs